United States - English - NLM (National Library of Medicine)

chiesi usa, inc. - reteplase (unii: dqa630rie9) (reteplase - unii:dqa630rie9) - retavase is indicated for use in acute st-elevation myocardial infarction (stemi) to reduce the risk of death and heart failure. limitation of use: the risk of stroke may outweigh the benefit produced by thrombolytic therapy in patients whose stemi puts them at low risk for death or heart failure. because thrombolytic therapy increases the risk of bleeding, retavase is contraindicated in the following situations: - active internal bleeding - recent stroke - intracranial or intraspinal surgery or serious head trauma within 3 months - intracranial conditions that increase the risk of bleeding (e.g. neoplasms, arteriovenous malformation, or aneurysms) - bleeding diathesis - current severe uncontrolled hypertension risk summary limited published data with retavase use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes.  in animal reproduction studies, reteplase administered to pregnant rabbits resulted in hemorrhaging in the genital tract, leading to abortions i